Up date in the management of advanced ovarian carcinoma

被引：35

作者：

Conte, PF ^{[1
]}

Cianci, C

Gadducci, A

机构：

[1] St Chiara Hosp & Univ, Dept Oncol, Div Med Oncol, Pisa, Italy

[2] St Chiara Hosp & Univ, Dept Procreat Med, Div Obstet & Gynecol, Pisa, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 1999年 / 32卷 / 01期

关键词：

D O I：

10.1016/S1040-8428(99)00036-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：49 / 58

页数：10

共 113 条

[1] Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].

Aabo, K ;

Adams, M ;

Adnitt, P ;

Alberts, DS ;

Athanazziou, A ;

Barley, V ;

Bell, DR ;

Bianchi, U ;

Bolis, G ;

Brady, MF ;

Brodovsky, HS ;

Bruckner, H ;

Buyse, M ;

Canetta, R ;

Chylak, V ;

Cohen, CJ ;

Colombo, N ;

Conte, PF ;

Crowther, D ;

Edmonson, JH ;

Gennatas, C ;

Gilbey, E ;

Gore, M ;

Guthrie, D ;

Kaye, SB ;

Laing, AH ;

Landoni, F ;

Leonard, RC ;

Lewis, C ;

Liu, PY ;

Mangioni, C ;

Marsoni, S ;

Meerpohl, H ;

Omura, GA ;

Parmar, MKB ;

Pater, J ;

Pecorelli, S ;

Presti, M ;

Sauerbrei, W ;

Skarlos, DV ;

Smalley, RV ;

Solomon, HJ ;

Stewart, LA ;

Sturgeon, JFG ;

Tattersall, MHN ;

Wharton, JT ;

Huinink, WWT ;

Tomirotti, M ;

Torri, W ;

Trope, C .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487

[2] Chemotherapy for ovarian cancer - a consensus statement on standard practice [J].

Adams, M ;

Calvert, AH ;

Carmichael, J ;

Clark, PI ;

Coleman, RE ;

Earl, HM ;

Gallagher, CJ ;

Ganesan, TS ;

Gore, ME ;

Graham, JD ;

Harper, PG ;

Jayson, GC ;

Kaye, SB ;

Ledermann, JA ;

Osborne, RJ ;

Perren, TJ ;

Poole, CJ ;

Radford, JA ;

Rustin, GJS ;

Slevin, ML ;

Smyth, JF ;

Thomas, H ;

Wilkinson, PM .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1404-1406

[3] Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer [J].

Aghajanian, C ;

Fennelly, D ;

Shapiro, F ;

Waltzman, R ;

Almadrones, L ;

O'Flaherty, C ;

O'Conner, K ;

Venkatraman, E ;

Barakat, R ;

Curtin, J ;

Brown, C ;

Reich, L ;

Wuest, D ;

Norton, L ;

Hoskins, W ;

Spriggs, DR .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1852-1860

[4] IMPACT OF DOXORUBICIN ON SURVIVAL IN ADVANCED OVARIAN-CANCER [J].

AHERN, RP ;

GORE, ME .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :726-732

[5] IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].

ALBERTS, DS ;

GREEN, S ;

HANNIGAN, EV ;

OTOOLE, R ;

STOCKNOVACK, D ;

ANDERSON, P ;

SURWIT, EA ;

MALVLYA, VK ;

NAHHAS, WA ;

JOLLES, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717

[6] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[7]

[Anonymous], 1995, JAMA, V273, P491

[8]

[Anonymous], INT J GYNECOLOGIC S2

[9]

BAKER TR, 1994, CANCER, V74, P656, DOI 10.1002/1097-0142(19940715)74:2<656::AID-CNCR2820740218>3.0.CO

[10]

2-6

← 1 2 3 4 5 6 7 8 9 10 →